Entinostat for treatment of solid tumors and hematologic malignancies

Expert Opinion on Investigational Drugs

Volumn 20, Issue 10, 2011, Pages 1455-1467

  Knipstein, Jeffrey ^a   Gore, Lia ^b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Entinostat; Epigenetics; HDAC inhibitor; Phase I trial; Phase II trial

Indexed keywords

AMINOTRANSFERASE; ANASTROZOLE; AROMATASE INHIBITOR; AZACITIDINE; CASPASE 3; CASPASE 8; CLOFARABINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; ERLOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HORMONE; IMMUNOMODULATING AGENT; LACTATE DEHYDROGENASE; MOCETINOSTAT; MS 27275; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; ROMIDEPSIN; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACTEREMIA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARCINOID; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLON CARCINOMA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DNA REPAIR; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EWING SARCOMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; META ANALYSIS; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PEER REVIEW; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PNEUMONIA; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; RECTUM CARCINOMA; SARCOMA; SIDE EFFECT; SMALL INTESTINE CANCER; SOLID TUMOR; STAPHYLOCOCCAL BACTEREMIA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; BENZAMIDES; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PYRIDINES;

EID: 80052703387     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.613822     Document Type: Article

References (86)

1. Hu E, Dul E, Sung CM, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307(2):720-8 (Pubitemid 37310689)
2. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26(37):5541-52 (Pubitemid 47255934)
3. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912-22. (Pubitemid 46218694)
4. Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18 Pt 1):5411-17. (Pubitemid 47510368)
5. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90. (Pubitemid 46482071)
6. Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14(14):4517-25.
7. Hauschild A, Trefzer U, Garbe C, et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]- benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008;18(4):274-8.
8. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32 (Pubitemid 47255924)
9. Fouladi M. Histone deacetylase inhibitors in cancer therapy. Cancer Invest 2006;24(5):521-7 (Pubitemid 44576406)
10. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15(12):3958-69
11. Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5
12. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9. (Pubitemid 46053039)
13. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-52 (Pubitemid 350106355)
14. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009;45(11):787-95
15. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17.
16. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010;22(5):431-6
17. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96(8):4592-7. (Pubitemid 29190381)
18. Suzuki T, Ando T, Tsuchiya K, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999;42(15):3001-3. (Pubitemid 29370445)
19. Simonini MV, Camargo LM, Dong E, et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103(5):1587-92 (Pubitemid 43191209)
20. Acharya MR, Sparreboom A, Sausville EA, et al. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2006;57(3):275-81 (Pubitemid 41827349)
21. Acharya MR, Karp JE, Sausville EA, et al. Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006;24(5):367-75 (Pubitemid 43876072)
22. Vire B, de Walque S, Restouin A, et al. Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS One 2009;4(9):e7085
23. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun Nterminal kinase 1 activation. Mol Cell Biol 2005;25(13):5429-44 (Pubitemid 40853579)
24. Nishioka C, Ikezoe T, Yang J, et al. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008;22(12):2159-68.
25. Tsapis M, Lieb M, Manzo F, et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 2007;39(7-8):1500-9 (Pubitemid 47031039)
26. Lucas DM, Davis ME, Parthun MR, et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004;18(7):1207-14 (Pubitemid 39023130)
27. Maggio SC, Rosato RR, Kramer LB, et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004;64(7):2590-600 (Pubitemid 38523917)
28. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63(13):3637-45 (Pubitemid 36793047)
29. Nishioka C, Ikezoe T, Yang J, et al. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 2008;22(7):1449-52 (Pubitemid 352006093)
30. Nishioka C, Ikezoe T, Yang J, et al. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008;32(9):1382-92
31. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110(1):267-77 (Pubitemid 47026844)
32. Gao S, Mobley A, Miller C, et al. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res 2008;32(5):771-80 (Pubitemid 351323931)
33. Lee CK, Wang S, Huang X, et al. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010;296(2):233-40
34. Sato T, Suzuki M, Sato Y, et al. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006;28(5):1233-41
35. Bracker TU, Sommer A, Fichtner I, et al. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 2009;35(4):909-20
36. Flis S, Gnyszka A, Splawinski J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 2009;387(2):336-41
37. Flis S, Gnyszka A, Flis K, Splawinski J. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. Eur J Pharmacol 2010;627(1-3):26-32
38. Zhang Y, Adachi M, Zhao X, et al. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl) amino-methyl] benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 2004;110(2):301-8 (Pubitemid 38580407)
39. Belinsky SA, Grimes MJ, Picchi MA, et al. Combination therapy with Vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011;71(2):454-62.
40. Witta SE, Dziadziuszko R, Yoshida K, et al. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 2009;20(4):689-95
41. Brazelle W, Kreahling JM, Gemmer J, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 2010;5(12):e14335
42. Kakihana M, Ohira T, Chan D, et al. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol 2009;4(12):1455-65
43. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66(2):944-50 (Pubitemid 43165962)
44. Qian DZ, Wei YF, Wang X, et al. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 2007;67(11):1182-93 (Pubitemid 47221885)
45. Nguyen TL, Abdelbary H, Arguello M, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008;105(39):14981-6
46. Bjorkman M, Iljin K, Halonen P, et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008;123(12):2774-81
47. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64(1):316-21 (Pubitemid 38114113)
48. Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004;10(18 Pt 1):6066-71 (Pubitemid 39302609)
49. Chen CS, Wang YC, Yang HC, et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007;67(11):5318-27.
50. Schmudde M, Braun A, Pende D, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 2008;272(1):110-21
51. Gediya LK, Belosay A, Khandelwal A, et al. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem 2008;16(6):3352-60 (Pubitemid 351418177)
52. Khandelwal A, Gediya L, Njar V. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer 2008;98(7):1234-43 (Pubitemid 351481680)
53. Sun P, Xia S, Lal B, et al. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 2009;27(7):1473-86
54. Eyupoglu IY, Hahnen E, Trankle C, et al. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006;5(5):1248-55 (Pubitemid 43881317)
55. Sabnis GJ, Goloubeva O, Chumsri S, et al. Functional activation of the Estrogen Receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011;71(5):1893-903.
56. Huang X, Gao L, Wang S, et al. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009;69(21):8403-11
57. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24(29):4609-23 (Pubitemid 41032599)
58. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010;9(12):3254-66.
59. Lee BI, Park SH, Kim JW, et al. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res 2001;61(3):931-4 (Pubitemid 32174406)
60. Xu J, Zhou JY, Wei WZ, et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008;68(16):6718-26
61. Qu W, Kang YD, Zhou MS, et al. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 2010;28(6):648-54
62. Baradari V, Huether A, Hopfner M, et al. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006;13(4):1237-50 (Pubitemid 46212577)
63. Dzieran J, Beck JF, Sonnemann J. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 2008;99(8):1685-92.
64. Gahr S, Peter G, Wissniowski TT, et al. The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep 2008;20(5):1249-56
65. Wang XF, Qian DZ, Ren M, et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005;11(9):3535-42 (Pubitemid 40627909)
66. Kato Y, Yoshimura K, Shin T, et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007;13(15 Pt 1):4538-46. (Pubitemid 47219724)
67. Holsken A, Eyupoglu IY, Lueders M, et al. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 2006;112(2):205-15
68. Liu S, Cheng H, Kwan W, et al. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther 2008;7(6):1751-61
69. Baradari V, Hopfner M, Huether A, et al. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007;13(33):4458-66 (Pubitemid 47412408)
70. Altmann A, Eisenhut M, Bauder-Wust U, et al. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 2010;37(12):2286-97
71. Hacker S, Dittrich A, Mohr A, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28(35):3097-110
72. Furchert SE, Lanvers-Kaminsky C, Juurgens H, et al. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120(8):1787-94 (Pubitemid 46399367)
73. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62(21):6108-15. (Pubitemid 35244459)
74. Aguilera DG, Das CM, Sinnappah-Kang ND, et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009;93(3):303-18
75. Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 2008;14(10):3113-23
76. Sonnemann J, Dreyer L, Hartwig M, et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 2007;133(11):847-58 (Pubitemid 350218911)
77. Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 2008;8:16
78. Mellert HS, Stanek TJ, Sykes SM, et al. Deacetylation of the DNA-binding Domain Regulates p53-mediated Apoptosis. J Biol Chem 2011;286(6):4264-70.
79. Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2(2):151-63
80. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(3):673-8 (Pubitemid 40282724)
81. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006;66(13):6785-92 (Pubitemid 44085638)
82. Di Bernardo G, Alessio N, Dell'Aversana C, et al. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 2010;225(2):537-44
83. Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 2009;32(3):480-2
84. Juergens RAVF, Coleman B, Sebree RS, et al. Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC). J Clin Oncol 2008;26:abstract #19036.
85. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114(13):2764-73.
86. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003 (Pubitemid 44078086)